Molecular Partners prices $64M IPO, falling short of original goal

Molecular Partners has priced its IPO, setting it up to raise $63.8 million to fund work on oncology and infectious disease candidates. The IPO haul is set to fall well short of the original target after a five-day period in which the biotech’s share price in Switzerland fell 17%.